{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-137040","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2022-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.700504+00:00","generated_at":"2026-06-26T02:07:02.424438+00:00","sec_items":["2.05","5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cortexyme cuts 36% more staff (67% total); CMO Michael Detke departs May 2","bullets":["Additional 36% headcount reduction, bringing total to 67% from January 2022 levels; majority by end of May 2022.","Estimated $0.7M in cash expenses for severance and related costs.","CMO Michael Detke to step down effective May 2, 2022; cash severance of $354,750 (9 months base salary).","Additional cash severance and accelerated vesting if change in control within 3 months of departure.","Cost reductions triggered by clinical hold on atuzaginstat (COR388) IND."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-137040","json":"https://secwatch.observer/filing/0001193125-22-137040.json","markdown":"https://secwatch.observer/filing/0001193125-22-137040.md","text":"https://secwatch.observer/filing/0001193125-22-137040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522137040/0001193125-22-137040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522137040/d310630d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T02:07:02.424438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56424a3f17","claim":"Michael Detke departed as Chief Medical Officer at Quince Therapeutics, Inc..","evidence_excerpt":"Effective May 2, 2022 (the “Departure Date”), Michael Detke, M.D., Ph.D., the Company’s Chief Medical Officer, will step down from his position as the Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662774/000119312522137040/0001193125-22-137040-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}